XORTX Therapeutics Inc.

Overview

Compare with another stock.

• TickerXRTX on Nasdaq²
• IndustryPharmaceutical Preparations²
• HeadquartersCalgary, Canada²
• Incorporated inBritish Columbia, Canada⁴
• Business addressSuite 2400 - 745 Thurlow Street, Vancouver, A1 V6E 0C5⁴
• Filer categoryNon-accelerated filer, Emerging growth company⁴
• Legal formCorporation²
• LEI254900RAT3XZPF9F9350²
• StatusActive²
• LEI statusLapsed (not renewed)²
• Registered address745 Thurlow Street, V6E 0C5 Vancouver, Canada²
• Registered withBC Registry Services, BC0911882²

See how the biggest companies compare on our leaderboards

The Company was incorporated to carry on business under the Business Corporations Act (British Columbia) (the “ BCBCA ”) as “APAC Resources Inc.” on May 31, 2011 and with registration number BC0911882. XORTX Pharma Corp. (“ XORTX Pharma ”) was incorporated under the laws of Alberta, Canada on August 24, 2012 under the name ReVasCor Inc. and was continued under the Canada Business Corporations Act on February 27, 2013 under the name of XORTX Pharma Corp. XORTX Pharma completed a reverse take-over transaction on January 10, 2018 (the “ RTO ”) with the Company. As part of this transaction, the Company changed its name to its current name: “XORTX Therapeutics Inc.” XORTX Pharma remains as a wholly owned subsidiary of the Company and is the Company’s only subsidiary.⁵ From its latest annual report

Corporate structure

XORTX Therapeutics Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What XORTX Therapeutics Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

Leadership

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive Officer, DirectorAllen Davidoff named Oct 31, 2024⁷
• Executive OfficerJames Fairbairn named Oct 31, 2024⁷
• Executive OfficerStacy Evans named Oct 31, 2024⁷
• Executive OfficerStephen Haworth named Oct 31, 2024⁷
• DirectorAbigail J. Jenkins named Oct 31, 2024⁷
• DirectorAnthony J. Giovinazzo named Oct 31, 2024⁷
• DirectorPatrick J. Treanor named Oct 31, 2024⁷
• DirectorPaul J. Van Damme named Oct 31, 2024⁷
• DirectorRaymond J. Pratt named Oct 31, 2024⁷
• DirectorWilliam Farley named Oct 31, 2024⁷

Calendar

Coming up

1. Nov 13, 2026Reports results for the quarter ending Sep/2026⁸

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

278 filings to the SEC since October 2021: 6 annual reports, 5 large holders, 1 private raises, 266 other. The latest 20:

1. Oct 8, 20266-K EDGAR
2. Sep 18, 20266-K EDGAR
3. Sep 10, 20266-K EDGAR
4. Sep 9, 20266-K EDGAR
5. Sep 4, 20266-K EDGAR
6. Aug 28, 20266-K EDGAR
7. Aug 17, 20266-K EDGAR
8. Aug 4, 20266-K EDGAR
9. Jul 29, 20266-K EDGAR
10. Jun 15, 20266-K EDGAR
11. Jun 12, 20266-K EDGAR
12. May 19, 20266-K EDGAR
13. May 19, 20266-K EDGAR
14. May 15, 2026424B4 EDGAR
15. May 14, 20266-K EDGAR
16. May 13, 2026EFFECT EDGAR
17. May 8, 20266-K EDGAR
18. May 8, 2026POS AM EDGAR
19. Apr 23, 2026POS AM EDGAR
20. Apr 22, 2026POS AM EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Lincoln Alternative Strategies LLCSCHEDULE 13G, 1 filing Oct 27, 2025⁹
• ARMISTICE CAPITAL, LLCSCHEDULE 13G/A, 4 filings Feb 14, 2023 to May 15, 2025¹⁰

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. Oct 18, 2024Filed a private offering of equity⁷ Form D: $1.8 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How XORTX Therapeutics Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARXORTX Therapeutics Inc.¹
• CIK0001729214
• Filer statusNon-accelerated filer an emerging growth company; not a shell company⁵
• Incorporated inBritish Columbia, Canada⁵
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business addressSuite 2400 - 745 Thurlow Street, Vancouver, A1 V6E 0C5¹
• Phone403-607-2621¹
• Shares outstanding6,962,218 shares as of Dec 31, 2025⁵
• AuditorSmythe LLP, Vancouver, Canada PCAOB ID 731⁵
• On EDGAR sinceJan 25, 2018¹
• Filings291 in all: 6-K (179), 424B3 (27), CORRESP (15), EFFECT (9), UPLOAD (7), F-1/A (6), POS AM (6), 20-F (5)¹
  All 28 form types

  424B5 (5), F-1 (4), 424B4 (3), DRS (3), NT 20-F (3), 6-K/A (2), D (2), SCHEDULE 13G (2), SEC STAFF LETTER (2), 20-F/A (1), 8-A12B (1), 8-A12B/A (1), CERT (1), DRS/A (1), DRSLTR (1), F-3 (1), S-8 (1), SC 13G (1), SC 13G/A (1), SCHEDULE 13G/A (1)

• Latest filingsAnnual report (20-F) Mar 20, 2026

Securities registered for trading

From the cover page of the 20-F filed Mar 20, 2026 (Section 12(b) of the Exchange Act).⁵